US Stock MarketDetailed Quotes

NVS Novartis AG

Watchlist

106.610
+1.180+1.12%

Close Feb 18 16:00 ET

106.500
-0.110-0.10%

Post 18:58 ET

210.56BMarket Cap18.16P/E (TTM)

Novartis AG Stock Forum

Asherboy88

Jan 27 07:41

Don't know why

$Novartis AG (NVS.US)$ why this stock keeps falling despite so many good news. Can someone enlighten pls

10xStockPicks

Jan 23 07:47

Today 3 Analysts Place BUY Ratings On This $2 Stock $7,$9 & $16 Which Is An Acquisition Target by BIG Pharma

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...

Stock_Drift

Dec 19, 2024 05:18

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

Asherboy88

Dec 11, 2024 08:09

$Novartis AG (NVS.US)$ what is happening ?? keeps going down

Movers and Shakers

Nov 21, 2024 07:11

Columns Today's Pre-Market Movers and Top Ratings | MSTR, NVDA, SNOW, PANW and More

Morning Movers
Gapping up
$Deere (DE.US)$ 's stock rose by 1.6% following their announcement of fourth-quarter earnings that surpassed analyst forecasts, despite substantial market hurdles.
Cryptocurrency-related stocks experienced a widespread surge. $Strategy (MSTR.US)$ saw a significant increase, jumping over 13%, while $MARA Holdings (MARA.US)$ climbed more than 11%.
$Snowflake (SNOW.US)$ 's shares surged 23.3% as ...

Bitcoin swings: What’s next for the Crypto craze?

10xStockPicks

Nov 15, 2024 08:23

ESPR Will Propel Higher, Events This Weekend & Analyst Event Next Week, Stock Price

This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...